MarketCap
Facebook
X
Telegram
Paratek Pharmaceuticals DIO Ratio | PRTK
Annual DIO Ratio Paratek Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 218 | 217 | 551 | 638 | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 638 | 217 | 406 |
Quarterly DIO Ratio Paratek Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 265 | 223 | - | 353 | 241 | 310 | - | 178 | 103 | 477 | - | 839 | 635 | 777 | - | 781 | 768 | 571 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 839 | 103 | 466 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Esperion Therapeutics
ESPR
|
2.46 K | - | - | $ 661 M |  USA |
 |
Evofem Biosciences
EVFM
|
107 | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
5.1 | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
2.26 K | - | - | $ 889 M | USA |
 |
Amicus Therapeutics
FOLD
|
870 | - | - | $ 4.47 B | USA |
 |
Happiness Biotech Group Limited
HAPP
|
11.6 | - | 1.35 % | $ 17.8 M |  China |
 |
Novavax
NVAX
|
50.7 | $ 10.15 | -6.8 % | $ 1.64 B | USA |
 |
KalVista Pharmaceuticals
KALV
|
203 | - | - | $ 1.45 B |  Britain |
 |
KemPharm
KMPH
|
41.1 | - | -0.34 % | $ 200 M | USA |
 |
NovaBay Pharmaceuticals
NBY
|
70 | - | - | $ 11.3 M | USA |
 |
OncoCyte Corporation
OCX
|
89.3 | - | 17.22 % | $ 355 K | USA |
 |
Verastem
VSTM
|
403 | $ 8.74 | 0.52 % | $ 606 M | USA |
 |
Plus Therapeutics
PSTV
|
937 | - | - | $ 301 M | USA |
 |
Qualigen Therapeutics
QLGN
|
60.6 | - | 5.59 % | $ 1.16 M | USA |
 |
Qilian International Holding Group Limited
QLI
|
145 | - | -6.08 % | $ 184 M | China |
 |
Salarius Pharmaceuticals
SLRX
|
158 | - | - | $ 2.64 M | USA |
 |
Sonnet BioTherapeutics Holdings
SONN
|
4.35 | - | - | $ 826 K | USA |
|
Windtree Therapeutics
WINT
|
70.2 | - | - | $ 26.8 M | USA |